Sensorion SA (ALSEN) | Financial Analysis & Statements
Sensorion SA Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
57.9M
Total Liabilities
13.4M
Shareholders Equity
44.5M
Debt to Equity
0.30
Cash Flow Metrics
Revenue & Profitability Trend
Sensorion SA Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 140.0K | 3.3M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 28.8M | 25.7M | 22.8M | 22.9M | 14.6M |
| Selling, General & Administrative | 3.1M | 4.5M | 2.4M | 130.6K | 106.0K |
| Other Operating Expenses | -4.4M | -3.7M | -4.4M | 1.8M | 2.1M |
| Total Operating Expenses | 27.5M | 26.4M | 20.8M | 24.9M | 16.8M |
| Operating Income | -30.8M | -28.4M | -22.3M | -23.1M | -15.0M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | -16,493.6% | -449.8% |
| Non-Operating Items | |||||
| Interest Income | 1.6M | 2.9M | 708.0K | 95.6K | 53.6K |
| Interest Expense | 211.0K | 251.0K | 109.0K | 168.0K | 165.7K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -29.4M | -25.8M | -21.8M | -23.2M | -15.1M |
| Income Tax | 4.0K | 126.0K | 297.0K | 0 | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -29.4M | -26.0M | -22.1M | -23.2M | -15.1M |
| Net Margin % | 0.0% | 0.0% | 0.0% | -16,572.0% | -453.8% |
| Key Metrics | |||||
| EBITDA | -29.0M | -25.4M | -21.5M | -22.3M | -14.5M |
| EPS (Basic) | €-0.10 | €-0.09 | €-0.18 | €-0.29 | €-0.19 |
| EPS (Diluted) | €-0.10 | €-0.09 | €-0.18 | €-0.29 | €-0.19 |
| Basic Shares Outstanding | 300417376 | 283969129 | 122501538 | 79837084 | 79691358 |
| Diluted Shares Outstanding | 300417376 | 283969129 | 122501538 | 79837084 | 79691358 |
Income Statement Trend
Sensorion SA Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 47.5M | 66.8M | 37.0M | 26.2M | 50.0M |
| Short-term Investments | - | 10.2M | - | - | - |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | - | - | 8.7K | 14.1K | 545.5K |
| Total Current Assets | 54.9M | 85.7M | 43.3M | 35.8M | 56.9M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 3.4M | 3.2M | 2.3M | 1.7M | 1.0M |
| Goodwill | 989.0K | 745.0K | 506.0K | 483.1K | 569.7K |
| Intangible Assets | 989.0K | 745.0K | 506.0K | 478.3K | 569.7K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.0K | 4.0K | -211.0K | - | -1 |
| Total Non-Current Assets | 3.0M | 3.6M | 3.2M | 3.2M | 2.1M |
| Total Assets | 57.9M | 89.3M | 46.5M | 38.9M | 59.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 5.6M | 6.9M | 3.7M | 7.3M | 5.0M |
| Short-term Debt | 1.2M | 1.2M | 1.1M | 1.2M | 711.4K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | 91.0K | 237.0K | 477.5K | 400.0K |
| Total Current Liabilities | 12.0M | 13.7M | 9.6M | 13.6M | 10.5M |
| Non-Current Liabilities | |||||
| Long-term Debt | 124.0K | 1.0M | 1.8M | 2.6M | 3.4M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 1.0M | 2.2M | 1.6M | 681.5K | 1.0M |
| Total Non-Current Liabilities | 1.4M | 3.5M | 3.6M | 3.5M | 4.5M |
| Total Liabilities | 13.4M | 17.1M | 13.2M | 17.1M | 15.0M |
| Equity | |||||
| Common Stock | 30.1M | 30.1M | 18.7M | 8.0M | 8.0M |
| Retained Earnings | -64.6M | -61.9M | -58.6M | -23.2M | -15.1M |
| Treasury Stock | 119.0K | 82.0K | 86.0K | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 44.5M | 72.1M | 33.3M | 21.9M | 44.1M |
| Key Metrics | |||||
| Total Debt | 1.3M | 2.2M | 2.9M | 3.9M | 4.1M |
| Working Capital | 42.9M | 72.0M | 33.7M | 22.2M | 46.4M |
Balance Sheet Composition
Sensorion SA Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -29.4M | -26.0M | -22.1M | -23.2M | -15.1M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 1.6M | 1.0M | 298.0K | 1.1M | 561.1K |
| Working Capital Changes | -618.0K | 184.0K | -831.0K | -2.5M | 482.9K |
| Operating Cash Flow | -27.9M | -24.7M | -22.5M | -24.6M | -14.1M |
| Investing Activities | |||||
| Capital Expenditures | -253.0K | -705.0K | -657.0K | -1.4M | -470.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | -6.1K | -29.6K | -33.3K |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -254.0K | -719.0K | -669.1K | -1.5M | -503.3K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | -846.0K | -893.0K | -1.1M | - | - |
| Financing Cash Flow | -724.0K | 67.0M | 33.1M | -488.0K | -557.6K |
| Free Cash Flow | -28.0M | -22.5M | -21.6M | -22.9M | -11.4M |
| Net Change in Cash | -28.8M | 41.5M | 10.0M | -26.5M | -15.2M |
Cash Flow Trend
Sensorion SA Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-3.79
Forward P/E
-5.05
Price to Book
2.56
Price to Sales
33.50
PEG Ratio
-5.05
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-399.80%
Return on Equity
-50.47%
Return on Assets
-26.12%
Financial Health
Current Ratio
4.59
Debt to Equity
2.77
Beta
0.37
Per Share Data
EPS (TTM)
€-0.10
Book Value per Share
€0.15
Revenue per Share
€0.02
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ALSEN | 194.8M | -3.79 | 2.56 | -50.47% | 0.00% | 2.77 |
| Abivax SA | 7.6B | -19.88 | 16.56 | -135.58% | 0.00% | 7.05 |
| Nanobiotix | 1.4B | - | - | 28.36% | -73.52% | -1.13 |
| Medincell S.A | 831.6M | -37.35 | - | 112.65% | -61.49% | -2.40 |
| BNP Paribas Easy | 527.3M | 22.65 | - | -96.39% | -27.22% | 2.22 |
Financial data is updated regularly. All figures are in the company's reporting currency.